RNA therapeutics is the most exciting branch of medications, focusing on curing genetic diseases and viral infections. For instance, mRNA vaccines were developed recently to combat Covid-19 infection. Although the process of developing RNA based therapeutics has been slow, it surely plays a massive role in developing novel strategies to cure chronic illnesses.
According to Allied Market Research, the global RNA based therapeutics market is expected to reach $25.12 billion by 2030, growing at a CAGR of 17.6% from 2021 to 2030. Target specificity and selectivity of treatment and initiatives from the government for large-scale sequencing projects have boosted the growth of the market. The rise in investment from VC companies in start-ups that focus on developing RNA based therapeutics has been a prime factor that boosts the market growth.
Recently, a fast-growing start-up, Alltrna announced its plans to develop therapies based on transfer RNA (tRNA). As a family of RNA plays an instrumental role in building protein, the research on RNA-based therapies has gained global attention. The leaders at the company firmly believe that the study of tRNA could open new ways to treat chronic diseases where mutations in mRNA cause body cells to make faulty proteins. The start-up has focused on studying mRNA mutations and transferring the targeted amino acid to the ribosome, which could help in restoring the production of normal proteins. This could be the best way to treat genetic diseases.
Another start-up, Ceptur Therapeutics, that received $75 million Series A funding is from Rutgers University. The researchers at Rutgers University have been focusing on RNA and how to manipulate or control RNA to understand its functions and possibly cure genetic diseases including neurological disorders and blood cancers. They have developed U1 Adaptor technology that can silence defective genes that may cause diseases. The technology consists of short single strands of artificial RNA that are easy to deliver to various tissues and organs.
The research of BioNTech and Moderna, both leading biotechnology companies, have shed light on messenger RNA in order to end the Covid-19 pandemic. In cells, mRNA offers instructions about which proteins the body should make. These instructions last momentarily to maintain the order against viruses. However, the companies have to work together to study endless RNA (eRNA) as it has no loose ends for enzymes to latch onto and it can help maintain the protein expression for a larger period. In theory, if there is a way to give people eRNA artificially, they can manufacture their own self-healing proteins in their bodies, opening a new way to fight diseases and viral infections.
Such rapid investments and the focus of many start-ups to invent new ways to manipulate RNA and recreate proteins artificially have opened new opportunities. However, there is still a long way to go for clinical studies and human trials. But rise in research papers in the field and the active part of investment firms have encouraged researchers to explore the potential of RNA based therapeutics in treating genetic diseases.
No comments:
Post a Comment